Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Dr Himanshu Negi
Eligibility
Inclusion criteria
Inclusion criteria: All patients of head and neck cancer with primary site of malignancy at nasal cavity, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx and salivary glands undergoing concurrent chemoradiotherapy
Exclusion criteria
Exclusion criteria: Patient with prior history of radiation exposure. Patient with a known history of pre existing sensorineural hearing loss or middle ear pathology. Patient with history of receiving ototoxic drugs. Patient who are known case of Type 2 Diabetes Mellitus or Chronic Kidney Disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the incidence and severity of hearing loss in patients of head and neck cancer undergoing concurrent chemoradiotherapy using pre and post treatment Pure Tone AudiometryTimepoint: To assess the incidence and severity of hearing loss in patients of head and neck cancer undergoing concurrent chemoradiotherapy using pre and post treatment Pure Tone Audiometry(PTA), PTA will be assessed before start of chemoradiotherapy and then finally after 6 months of baseline PTA | — |
Secondary
| Measure | Time frame |
|---|---|
| To document the change in hearing thresholds across different frequencies (250 Hz - 8000Hz) post concurrent chemoradiotherapyTimepoint: From before start of chemoradiotherapy to after completion of chemoradiotherapy | — |
Countries
India
Contacts
Public ContactDr. Shahzad Ahmad
GMC HALDWANI
Outcome results
None listed